Daniel Sugrue

1.0k total citations
29 papers, 635 citations indexed

About

Daniel Sugrue is a scholar working on Cardiology and Cardiovascular Medicine, Epidemiology and Immunology. According to data from OpenAlex, Daniel Sugrue has authored 29 papers receiving a total of 635 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cardiology and Cardiovascular Medicine, 9 papers in Epidemiology and 5 papers in Immunology. Recurrent topics in Daniel Sugrue's work include Atrial Fibrillation Management and Outcomes (4 papers), Immune Cell Function and Interaction (4 papers) and Hepatitis C virus research (4 papers). Daniel Sugrue is often cited by papers focused on Atrial Fibrillation Management and Outcomes (4 papers), Immune Cell Function and Interaction (4 papers) and Hepatitis C virus research (4 papers). Daniel Sugrue collaborates with scholars based in United Kingdom, United States and Sweden. Daniel Sugrue's co-authors include Phil McEwan, Peter Tomašec, Gavin W. G. Wilkinson, Richard J. Stanton, Jason Gordon, James A. Davies, Virginie Prod’homme, Paul J. Lehner, Michael P. Weekes and Andrew J. Davison and has published in prestigious journals such as PLoS ONE, European Heart Journal and BMJ.

In The Last Decade

Daniel Sugrue

28 papers receiving 625 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Sugrue United Kingdom 13 306 208 111 62 57 29 635
Hadi Karimzadeh Iran 15 320 1.0× 135 0.6× 41 0.4× 30 0.5× 76 1.3× 53 720
A. Bionda Italy 11 191 0.6× 75 0.4× 74 0.7× 24 0.4× 41 0.7× 19 521
M. Le Bras France 13 186 0.6× 46 0.2× 24 0.2× 27 0.4× 40 0.7× 47 542
Jeffrey B. Halldorson United States 15 709 2.3× 145 0.7× 22 0.2× 39 0.6× 121 2.1× 30 1.6k
É. Thervet France 22 386 1.3× 119 0.6× 58 0.5× 199 3.2× 83 1.5× 47 1.5k
F Roudot-Thoraval France 15 766 2.5× 90 0.4× 19 0.2× 23 0.4× 59 1.0× 34 1.2k
D Bassetti Italy 13 210 0.7× 201 1.0× 21 0.2× 14 0.2× 112 2.0× 27 839
Yao Xu China 11 135 0.4× 185 0.9× 18 0.2× 18 0.3× 96 1.7× 27 708
Shinn‐Cherng Chen Taiwan 25 1.8k 5.8× 107 0.5× 74 0.7× 18 0.3× 95 1.7× 117 2.2k
Aggrey Dhabangi Uganda 16 110 0.4× 163 0.8× 15 0.1× 9 0.1× 78 1.4× 40 776

Countries citing papers authored by Daniel Sugrue

Since Specialization
Citations

This map shows the geographic impact of Daniel Sugrue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Sugrue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Sugrue more than expected).

Fields of papers citing papers by Daniel Sugrue

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Sugrue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Sugrue. The network helps show where Daniel Sugrue may publish in the future.

Co-authorship network of co-authors of Daniel Sugrue

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Sugrue. A scholar is included among the top collaborators of Daniel Sugrue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Sugrue. Daniel Sugrue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Choy, Ernest, et al.. (2021). Outcomes in rheumatoid arthritis patients treated with abatacept: a UK multi-centre observational study. BMC Rheumatology. 5(1). 3–3. 6 indexed citations
3.
Jassem, Ahmed Majeed, et al.. (2021). Cost Effectiveness of Screening for Hepatitis C Virus in Iraq in the Era of Simplified Testing and Treatment. PharmacoEconomics. 39(11). 1327–1341. 2 indexed citations
4.
Darlington, Oliver, Marc Evans, Phil McEwan, et al.. (2021). Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review. Advances in Therapy. 38(2). 994–1010. 40 indexed citations
5.
Bem, Danai, Daniel Sugrue, Karin M. Butler, et al.. (2021). The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. Renal Failure. 43(1). 241–254. 12 indexed citations
6.
Hill, Nathan R., Chris Arden, A. John Camm, et al.. (2020). Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. Contemporary Clinical Trials. 99. 106191–106191. 16 indexed citations
7.
8.
9.
Hill, Nathan R., Daniel Ayoubkhani, Phil McEwan, et al.. (2019). Predicting atrial fibrillation in primary care using machine learning. PLoS ONE. 14(11). e0224582–e0224582. 90 indexed citations
10.
Sugrue, Daniel, et al.. (2019). Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. PharmacoEconomics. 37(12). 1451–1468. 38 indexed citations
11.
Sugrue, Daniel, et al.. (2018). Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design. Value in Health. 21. S267–S267. 7 indexed citations
12.
Darlington, Oliver, et al.. (2018). Estimating Health Outcomes in HIV Infected Patients Treated with a Dual Regimen of Dolutegravir and Rilpivirine in Europe. Value in Health. 21. S155–S155. 2 indexed citations
13.
Arthurs, Erin, et al.. (2018). Dolutegravir and Rilpivirine to Treat Virologically Suppressed Adults Living with HIV-1: A Canadian Cost-Utility Analysis. Value in Health. 21. S9–S10. 2 indexed citations
14.
Koning‐Ward, Tania F. de, Jason Gordon, Hayley Bennett, et al.. (2016). Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences. Public Health. 141. 42–51. 9 indexed citations
15.
Bennett, Hayley, Phil McEwan, Daniel Sugrue, Anupama Kalsekar, & Yong Yuan. (2015). Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. PLoS ONE. 10(5). e0125846–e0125846. 15 indexed citations
16.
Gordon, Jason, et al.. (2015). Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease. European Journal of Gastroenterology & Hepatology. 27(7). 804–812. 47 indexed citations
17.
Fielding, Ceri A., Rebecca Aicheler, Richard J. Stanton, et al.. (2014). Two Novel Human Cytomegalovirus NK Cell Evasion Functions Target MICA for Lysosomal Degradation. PLoS Pathogens. 10(5). e1004058–e1004058. 112 indexed citations
18.
Groarke, John D., Zita Galvin, Catherine McGorrian, et al.. (2013). The Brady Bunch? New evidence for nominative determinism in patients' health: retrospective, population based cohort study. BMJ. 347(dec12 3). f6627–f6627. 4 indexed citations
19.
Blake, G, et al.. (2011). Increasing cardiac interventions among the aged.. PubMed. 103(10). 308–10. 1 indexed citations
20.
Prod’homme, Virginie, Daniel Sugrue, Richard J. Stanton, et al.. (2010). Human cytomegalovirus UL141 promotes efficient downregulation of the natural killer cell activating ligand CD112. Journal of General Virology. 91(8). 2034–2039. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hadi Karimzadeh Breakdown of academic impact, for papers by A. Bionda Breakdown of academic impact, for papers by M. Le Bras Breakdown of academic impact, for papers by Jeffrey B. Halldorson Breakdown of academic impact, for papers by É. Thervet Breakdown of academic impact, for papers by F Roudot-Thoraval Breakdown of academic impact, for papers by D Bassetti Breakdown of academic impact, for papers by Yao Xu Breakdown of academic impact, for papers by Shinn‐Cherng Chen Breakdown of academic impact, for papers by Aggrey Dhabangi
Rankless by CCL
2026